YU81800A - POSTUPAK ZA DOBIJANJE INHIBITORA HMG-CoA REDUKTAZE VISOKE ČISTOĆE - Google Patents

POSTUPAK ZA DOBIJANJE INHIBITORA HMG-CoA REDUKTAZE VISOKE ČISTOĆE

Info

Publication number
YU81800A
YU81800A YU81800A YU81800A YU81800A YU 81800 A YU81800 A YU 81800A YU 81800 A YU81800 A YU 81800A YU 81800 A YU81800 A YU 81800A YU 81800 A YU81800 A YU 81800A
Authority
YU
Yugoslavia
Prior art keywords
coa reductase
reductase inhibitors
hmg
purity
chemical synthesis
Prior art date
Application number
YU81800A
Other languages
English (en)
Inventor
Rok Grahek
Dušan Milivojević
Andrej Bastarda
Original Assignee
Lek Pharmaceutical And Chemical Company D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceutical And Chemical Company D.D. filed Critical Lek Pharmaceutical And Chemical Company D.D.
Publication of YU81800A publication Critical patent/YU81800A/sh
Publication of RS49996B publication Critical patent/RS49996B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/422—Displacement mode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin i njihovi derivati i analozi su poznati kao inhibitori HMG-CoA reduktaze i upotrebljavaju se kao antihiperholesterolemijski agensi. Najveci deo njih se proizvodi fermentacijom, upotrebom mikroorganizama razlicitih vrsta, odredjenih kao vrste koje pripadaju Aspergillus, Monascus, Nocardia, Amicolatopsis, Mucor ili Penicillium genus, neki se dobijaju tretmanom proizvoda fermentacije koriscenjem metoda hemijske sinteze ili su proizvodi totalne hemijske sinteze. Cistoca aktivnog sastojka je vazan faktor u proizvodnji bezbednog i delotvornog farmaceutskog preparata narocito, ukoliko se farmaceutski proizvod mora koristiti tokom lecenja ili prevencije visokog plazmatskog holesterola, zasnovanih na duzem vremenskom periodu. Akumulacija necistoca iz farmaceutskih preparata nize cistoce moze prouzrokovati brojne sporedne efekte u toku lecenja. Ovaj pronalazak se odnosi na novi industrijski postupak za izolovanje inhibitora HMG-CoA reduktaze upotrebom takozvane, hromatografije istiskivanjem. Upotreba pronalaska omogucuje dobijanje inhibitora HMG-CoA reduktaze visoke cistoce, u visokim prinosima, sa niskim troskovima proizvodnje i pogodnim ekoloskim balansom.
YUP-818/00A 1998-09-18 1999-09-17 POSTUPAK ZA DOBIJANJE INHIBITORA HMG-CoA REDUKTAZE VISOKE ČISTOĆE RS49996B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI9800241A SI20072A (sl) 1998-09-18 1998-09-18 Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze

Publications (2)

Publication Number Publication Date
YU81800A true YU81800A (sh) 2003-02-28
RS49996B RS49996B (sr) 2008-09-29

Family

ID=20432332

Country Status (22)

Country Link
US (1) US6695969B1 (sh)
EP (1) EP1114040B1 (sh)
JP (1) JP3795755B2 (sh)
KR (1) KR100607608B1 (sh)
CN (1) CN1186335C (sh)
AT (1) ATE284396T1 (sh)
AU (1) AU766630B2 (sh)
BG (1) BG64676B1 (sh)
CA (1) CA2343645A1 (sh)
DE (1) DE69922519T2 (sh)
HR (1) HRP20010045B1 (sh)
HU (1) HUP0102997A2 (sh)
IL (2) IL142056A0 (sh)
IS (1) IS2149B (sh)
NZ (1) NZ509582A (sh)
PL (1) PL200336B1 (sh)
RO (1) RO121116B1 (sh)
RS (1) RS49996B (sh)
RU (1) RU2235098C2 (sh)
SI (1) SI20072A (sh)
SK (1) SK285868B6 (sh)
WO (1) WO2000017182A1 (sh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141602B2 (en) * 1998-09-18 2006-11-28 Lek Pharmaceuticals D.D. Process for obtaining HMG-CoA reductase inhibitors of high purity
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
HUP9902352A1 (hu) * 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
RU2002114072A (ru) * 1999-11-30 2004-07-20 Биогал Джиоджисзерджиар РТ (HU) Способ выделения соединений статина из ферментационного бульона
CA2394200C (en) * 1999-12-14 2006-10-03 Biogal Gyogyszergyar Rt. Novel forms of pravastatin sodium
JP2003525935A (ja) 2000-03-03 2003-09-02 ビオガル ジョジセルジャール アール テー． 低下したレベルの二量体不純物を伴うロバスタチン及びシンバスタチンの精製方法
US6936731B2 (en) 2000-10-05 2005-08-30 TEVA Gyógyszergyár Részvénytársaság Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
CZ20031166A3 (cs) * 2000-10-05 2004-04-14 Biogal Gyogyszergyar Rt Sodná sůl pravastatinu, která v podstatě neobsahuje pravastatin lakton a epi-pravastatin a kompozice na její bázi
US20050215636A1 (en) * 2000-10-05 2005-09-29 Vilmos Keri Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
KR100407758B1 (ko) * 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
JP2003093045A (ja) * 2001-09-26 2003-04-02 Godo Shusei Co Ltd 有用変換微生物
KR100435078B1 (ko) * 2002-02-08 2004-06-09 종근당바이오 주식회사 심바스타틴의 정제방법
CA2521276A1 (en) * 2003-04-01 2004-10-14 Ranbaxy Laboratories Limited Fermentation process for the preparation of pravastatin
US6978908B2 (en) * 2003-09-15 2005-12-27 Gerber Products Company Drinking vessel with adjustable handles
PT1641447E (pt) * 2003-11-24 2008-12-10 Teva Gyogyszergyar Zartkoeruee Método de purificação da pravastatina
ES2239533B1 (es) * 2004-03-01 2006-12-16 Ercros Industrial, S.A. Procedimiento para la obtencion de compactina.
MX2007003652A (es) * 2004-09-28 2009-02-16 Teva Pharma Proceso para preparar formas de calcio de atorvastatina sustancialmente libre de impurezas.
CN102043030A (zh) * 2009-10-22 2011-05-04 北京万全阳光医学技术有限公司 一种用高效液相色谱法测定烟酸辛伐他汀缓释片有关物质的方法
CN102621238A (zh) * 2011-02-01 2012-08-01 北京北大维信生物科技有限公司 一种测定HMG-CoA还原酶抑制剂浓度的方法
CN105985244A (zh) * 2015-02-04 2016-10-05 北京北大维信生物科技有限公司 化合物、其分离方法、合成方法及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
IT1232311B (it) 1989-09-04 1992-01-28 Sclavo Spa Metodo di purificazione di composti a struttura peptidica o pseudo peptidica a basso peso molecolare.
US5202029A (en) * 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
AU661996B2 (en) * 1991-03-14 1995-08-17 Kabushiki Kaisha Ace Denken Stock control system
US5420024A (en) * 1993-05-11 1995-05-30 Merck & Co., Inc. Process for synthesis of acylated HMG-CoA reductase inhibitors from a lactone diol precursor using Candida cylindracea
US5427686A (en) * 1994-04-05 1995-06-27 Sri International Process for separating material from mixture using displacement chromatography
EP0877089A1 (en) * 1997-05-07 1998-11-11 Gist-Brocades B.V. HMG-CoA reductase inhibitor preparation process

Also Published As

Publication number Publication date
RO121116B1 (ro) 2006-12-29
KR20010099584A (ko) 2001-11-09
IS2149B (is) 2006-10-13
SI20072A (sl) 2000-04-30
JP2002526486A (ja) 2002-08-20
SK285868B6 (sk) 2007-10-04
HUP0102997A2 (hu) 2001-12-28
HRP20010045A2 (en) 2001-12-31
EP1114040B1 (en) 2004-12-08
KR100607608B1 (ko) 2006-08-02
RU2235098C2 (ru) 2004-08-27
NZ509582A (en) 2003-10-31
AU766630B2 (en) 2003-10-23
SK20022000A3 (sk) 2001-08-06
HRP20010045B1 (en) 2005-08-31
DE69922519T2 (de) 2005-12-08
ATE284396T1 (de) 2004-12-15
IL142056A0 (en) 2002-03-10
AU5528499A (en) 2000-04-10
RS49996B (sr) 2008-09-29
IS5886A (is) 2001-03-12
US6695969B1 (en) 2004-02-24
JP3795755B2 (ja) 2006-07-12
IL142056A (en) 2006-08-01
CA2343645A1 (en) 2000-03-30
CN1186335C (zh) 2005-01-26
DE69922519D1 (de) 2005-01-13
WO2000017182A1 (en) 2000-03-30
EP1114040A1 (en) 2001-07-11
BG105348A (en) 2001-11-30
PL345883A1 (en) 2002-01-14
CN1318063A (zh) 2001-10-17
BG64676B1 (bg) 2005-11-30
PL200336B1 (pl) 2008-12-31

Similar Documents

Publication Publication Date Title
YU81800A (sh) POSTUPAK ZA DOBIJANJE INHIBITORA HMG-CoA REDUKTAZE VISOKE ČISTOĆE
IL187261A0 (en) Crystals of the sodium salt of pravastatin
IL142055A0 (en) New salts of hmg-coa reductase inhibitors
IL143759A0 (en) STABLE PHARMACEUTICAL FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITORS
AU4943400A (en) Stabilized pharmaceutically effective composition and pharmaceutical formulationcomprising the same
AU1510800A (en) Process for the preparation of simvastatin and analogs thereof
EP1299340A2 (en) Process for the isolation of lovastatin
AU2000250960A1 (en) Stable pharmaceutical product and formulation
YU88602A (sh) Stabilizovane farmaceutski efektivne smeše i farmaceutske formulacije koje ih sadrže